NEWS & PUBLICATIONS
Latest news, events and publications from EPICS Therapeutics
News
EPICS Therapeutics presents compelling in vivo efficacy in oncology with its proprietary METTL3 inhibitor at AACR 2023
Press releases
EPICS Therapeutics initiates first-in-human studies with EP282, an oral investigational drug for the treatment of gastrointestinal inflammatory disorders and cancer
Publications
Expression of Free Fatty Acid Receptor 2 by Dendritic Cells Prevents Their Expression of Interleukin 27 and Is Required for Maintenance of Mucosal Barrier and Immune Response Against Colorectal Tumors in Mice
Publications
Metabolite-Sensing Receptor Ffar2 Regulates Colonic Group 3 Innate Lymphoid Cells and Gut Immunity
Press releases
EPICS Therapeutics to acquire Ogeda former assets, Adding Drug Discovery & Development Capabilities
For general information: info@epicstherapeutics.com
For press and media queries: media_relations@epicstx.com